Ekso Bionics to Report First Quarter 2025 Financial Results on May 5 – Conference Call to Follow
Rhea-AI Summary
Ekso Bionics (Nasdaq: EKSO), a leader in exoskeleton technology for medical and industrial applications, has scheduled its Q1 2025 financial results announcement for May 5, 2025, after market close.
The company will host a conference call on the same day at 1:30 PM Pacific Time (4:30 PM Eastern Time) to discuss:
- First quarter 2025 financial performance
- Recent business developments
- Company updates
Interested participants can join the conference call by dialing:
The presentation will be broadcast live and archived on the company's investor relations website at www.eksobionics.com under the "Presentations & Events" section.
Positive
- Scheduled earnings release indicates compliance with SEC reporting requirements and Nasdaq listing standards
- Maintaining investor communication through conference call with both domestic and international access
Negative
- None.
News Market Reaction
On the day this news was published, EKSO declined 3.50%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
SAN RAFAEL, Calif., April 28, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today announced that it will release financial and business results for the first quarter of 2025 after the close of trading on Monday, May 5, 2025. Management will host a conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET to review the financial results and discuss recent business developments.
To participate in the conference call by telephone, please dial 877-407-6184 (domestic) or 201-389-0877 (international). The call will also be broadcast live and archived on the Company’s website at www.eksobionics.com under “Presentations & Events” in the Investors section.
About Ekso Bionics®
Ekso Bionics® is a leading developer of exoskeleton solutions that amplify human potential by supporting or enhancing strength, endurance and mobility across medical and industrial applications. Based upon its industry-leading expertise, the Company focuses on improving health and quality of life with advanced robotics designed to enhance, amplify, and restore human function. Ekso Bionics is the only known exoskeleton company to offer technologies that range from helping those with paralysis to stand up and walk, to enhancing human capabilities on job sites across the globe. The Company is headquartered in the San Francisco Bay Area and is listed on the Nasdaq Capital Market under the symbol “EKSO.” For more information, visit: www.eksobionics.com.
Contact:
Stephen Kilmer
Investor Relations
Direct: (646) 274-3580
Email: skilmer@eksobionics.com
FAQ
When will Ekso Bionics (EKSO) release Q1 2025 earnings?
How can investors join EKSO's Q1 2025 earnings call?
Where can I watch EKSO's Q1 2025 earnings webcast?
What time is Ekso Bionics earnings call on May 5, 2025?
Will EKSO's Q1 2025 earnings call discuss recent business developments?
